百花医药此前发布的《关于筹划控制权变更事项的停牌公告》《关于筹划控制权变更事项继续停牌 的公告》及上述最新公告均未对交易方进行披露。 由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意见，本着审慎 的原则，决定终止本次控制权变更事项。公司目前各项经营情况正常，终止筹划控制权变更事项不会对 公司经营业绩和财务状况产生重大不利影响。为维护投资者利益，根据相关规定，经公司向上海证券交 易所申请，公司股票于 2026 年 1 月 7 日（星期三）开市起复牌。 中国经济网北京1月7日讯 百花医药(600721.SH)今日复牌跌停，截至收盘报11.02元，跌幅9.97%。 该股停牌前的最后一个交易日（2025年12月26日）盘中最高涨9.00%。 百花医药昨日晚间披露关于终止筹划控制权变更事项暨复牌的公告。因公司控股股东、实际控制人 米在齐、米恩华、杨小玲正在筹划公司股份协议转让事宜，该事项可能导致公司控制权发生变更。鉴于 该事项正在洽谈当中，尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造成公司股价异 常波动，经公司向上海证券交易所申请，公司股票自 2025 年 12 月 29 日（星 ...

百花医药(600721.SH)今日复牌一字板跌停，目前封单金额高达3.24元，现报11.2亿元，总市值42.38亿 元。消息上，百花医药昨日盘后公告，因公司控股股东、实际控制人与交易对方未就控制权变更相关重 大事项达成一致意见，决定终止本次控制权变更事项。业绩方面，2025年前三季度，百花医药营收为 2.986亿元，同比增长2.74%，净利润3267万元，同比增长36.41%。 ...

Policy Developments - The National Medical Products Administration (NMPA) aims for a drug inspection pass rate of over 99% by 2025, with 19,700 batches to be inspected, ensuring overall drug safety stability in the country [1] Drug and Device Approvals - Qianjin Pharmaceutical announced that it and its subsidiary received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg), enhancing its product pipeline for sustainable development [2] - Haizhi Pharmaceutical's subsidiary received acceptance for the listing application of HSK39297 tablets, intended for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitors [3] - Xuantai Pharmaceutical obtained a drug registration certificate for injectable Isavuconazole, which is used to treat invasive aspergillosis and mucormycosis in adults [4] Capital Market Insights - Xiangyu Medical reported that as of the end of 2025, its brain-computer interface products have not achieved large-scale sales, with revenue contribution remaining minimal due to delays in bidding and sales processes [5] - Sanbo Brain Science clarified that it does not engage in the research, production, or sales of brain-computer interface products, and the revenue from neuro-regulation technology is negligible [6] - Weisi Medical stated that its new products in the brain-computer interface field are still in the early market cultivation stage, with limited revenue contribution [7] - Qiangna Technology, a "unicorn" in the brain-computer interface sector, completed approximately 2 billion RMB in financing, marking the second-largest financing in the field after Neuralink [8] - Baihua Pharmaceutical announced the termination of its control change plan due to a lack of consensus with the controlling shareholder, with stock resuming trading on January 7, 2026 [9] Industry Developments - Puluo Pharmaceutical signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to collaborate on innovative drug research and outsourced production projects [10] - Yong'an Pharmaceutical plans to absorb and merge its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd., with recent financial data showing total assets of 180 million RMB and a net profit of -1.12 million RMB for the subsidiary [11] - Baiyang Pharmaceutical established a collaborative innovation laboratory with Capital Medical University Xuanwu Hospital to focus on cutting-edge medical research in neuroscience and thoracic surgery [12] - Insilico Medicine announced an $888 million collaboration with Servier for the development of anti-tumor drugs, with potential upfront payments and milestone payments involved [13] Public Sentiment Alerts - WuXi AppTec disclosed that shareholders controlled by the actual controller have cumulatively reduced their holdings by 59.6751 million shares, accounting for 2% of the total share capital, with the reduction completed on January 5, 2026 [14]

Summary of Key Points Core Viewpoint - Multiple shareholders from various companies are planning to reduce their stakes, indicating potential shifts in ownership and market dynamics [1]. Shareholder Reductions - **Shanwaishan**: Shareholders Yuanwaiyuan, Chongqing Dexiang, and Chongqing Derui plan to reduce a total of no more than 6.3747 million shares [1]. - **Oriental Zhongke**: Shareholder Dalian Jintou intends to reduce no more than 3% of its shares [1]. - **Mengke Pharmaceutical**: Shareholder Mengke Hong Kong plans to reduce no more than 3% of its shares [1]. - **Shengke Communication**: Shareholder National Integrated Circuit Industry Investment Fund plans to reduce no more than 3% of its shares [1]. - **Pioneer Electronics**: The controlling shareholder plans to reduce no more than 1% of its shares [1]. - **Heer Technology**: Chairman Liu Jianwei plans to reduce no more than 2% of his shares [1]. - **Sifang Jichuang**: The controlling shareholder and its concerted parties plan to reduce no more than 2% of their shares [1]. - **Yinbang Shares**: Shareholder Huaibei Public Utilities plans to reduce no more than 3% of its shares [1]. - **Fulaiwang**: The controlling shareholder plans to reduce no more than 2.9977% of its shares [1]. - **Thinking Control**: The company has terminated plans for a change in control and will resume trading on January 7 [1]. - **Baihua Pharmaceutical**: The company has also terminated plans for a change in control and will resume trading on January 7 [1].

Group 1 - The Ministry of Commerce announced that the "old-for-new" policy will drive consumer goods sales to reach 3.92 trillion yuan, benefiting 494 million consumers [3] - The policy will include support for the update of commercial facilities and energy-saving equipment, encouraging local governments to provide policy support for sorting center construction [3] - The "14th Five-Year Plan" aims to promote the construction of approximately 200 "waste-free cities" and increase the supply of high-quality green agricultural products [3] Group 2 - The People's Bank of China emphasized the importance of promoting high-quality economic development and reasonable price recovery in its monetary policy considerations [3] - The central bank plans to maintain ample liquidity and relatively loose social financing conditions to align monetary supply growth with economic growth and price level expectations [3] Group 3 - China Satcom issued a risk warning regarding its stock, which has increased by 108.64% since December 3, 2025, significantly outpacing the industry and market indices [5] - The company’s current price-to-earnings ratio stands at 704.09, far exceeding the industry average, indicating a potential risk of a significant price drop [5] Group 4 - Chipsource announced an investment in TianSui Chip Technology, acquiring control of ZhiDian Semiconductor, with a capital increase of 940 million yuan [6] - The company will hold a 40% stake in TianSui Chip Technology, becoming its largest shareholder [6] Group 5 - Aerospace Electronics reported a stock price increase of 123.23% since November 27, 2025, indicating a potential market overheating situation [7] - The stock's trading volume has been significant, raising concerns about the sustainability of its current price level [7] Group 6 - Keda Xunfei is collaborating with over 500 intelligent robot manufacturers, providing AI services based on its multi-modal perception and large model capabilities [7] - The company is positioned as a key player in the robotics industry, partnering with leading firms [7] Group 7 - Zhongtai Co. expects a net profit of 420 million to 480 million yuan for 2025, indicating a turnaround from losses [9] - Lier Chemical anticipates a net profit of 460 million to 500 million yuan, representing a year-on-year growth of 113.62% to 132.19% [9]

Market Overview - The US stock market closed higher, with the Dow Jones and S&P 500 indices reaching all-time closing highs. The S&P 500 rose by 0.62%, the Nasdaq increased by 0.65%, and the Dow Jones gained 0.99% [3] - The core drivers of the market were semiconductor and AI-related stocks, particularly following announcements from Nvidia's CEO regarding new AI processors and storage technology [3] - Semiconductor stocks performed exceptionally well, with SanDisk surging over 27%, Western Digital up 17%, Seagate Technology rising 14%, and Micron Technology increasing by 10% [3] - The Philadelphia Semiconductor Index rose by 2.75%, marking a historical record with a cumulative gain of approximately 8% in the first three trading days of the year [3] Technology Sector - Large tech stocks showed mixed performance, with Amazon leading at a 3.38% increase, followed by Microsoft at 1.20%. However, Tesla fell sharply by 4.14%, and Nvidia declined by 0.47% [3] - Chinese concept stocks faced pressure, with the Nasdaq Golden Dragon China Index dropping by 0.78%. Notable movements included a 70.83% surge in Zhongchi Chefu and a 3.18% increase in ASE Technology [4] Commodity Market - Gold prices continued to rise, with spot gold increasing by 0.8% to $4485.39 per ounce [5] - International oil prices retreated, with light crude oil futures for February delivery falling by 2.04% to $57.13 per barrel [5] Regulatory Developments - The Chinese Ministry of Commerce announced stricter export controls on dual-use items to Japan, effective immediately, to safeguard national security [6] - The People's Bank of China outlined its monetary policy for 2026, emphasizing a moderately loose approach and support for economic development and financial stability [6] Financial Sector Insights - Financial institutions anticipate an improvement in market liquidity due to increased credit issuance and fiscal fund allocation at the beginning of the year [9] - Analysts suggest that the Shanghai Composite Index may experience slight upward fluctuations, urging investors to monitor macroeconomic data and policy changes closely [9]

证券代码：600721 证券简称：百花医药（维权） 公告编号：2026-001 新疆百花村医药集团股份有限公司 关于终止筹划控制权变更事项暨复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 证券停复牌情况：适用 因新疆百花村医药集团股份有限公司（以下简称"百花医药"或"公司"）控股股东、实际控制人米在齐先 生、米恩华先生、杨小玲女士终止筹划本次控制权变更事项,本公司的相关证券停复牌情况如下： 登录新浪财经APP 搜索【信披】查看更多考评等级 由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意见，本着审慎的原 则，决定终止本次控制权变更事项。 公司目前各项经营情况正常，终止筹划控制权变更事项不会对公司经营业绩和财务状况产生重大不利影 响。 三、复牌安排 ■ 一、停牌情况概述 因公司控股股东、实际控制人米在齐先生、米恩华先生、杨小玲女士正在筹划公司股份协议转让事宜， 该事项可能导致公司控制权发生变更。鉴于该事项正在洽谈当中，尚存在不确定性，为保证公平信息披 露，维护投资者利益， ...

Group 1: Company Updates - ChaoYing Electronics has adjusted the investment amount for its AI computing power high-end printed circuit board expansion project from 1.468 billion RMB to 3.315 billion RMB, aiming to meet stronger demand for high-end PCB products and enhance overseas production capabilities [2] - Baihua Pharmaceutical and Siwei Control have both terminated their plans for control change due to a lack of consensus with the transaction parties, with their stocks set to resume trading on January 7, 2026 [3] - Aihui Long has signed a strategic cooperation framework agreement with Brain Machine Star Chain to enhance market expansion and sales of brain-machine interface products through its strong sales channels in emergency, brain disease diagnosis, and pediatrics [10] Group 2: Performance Forecasts - Zhongtai Co. expects a net profit of 420 million to 480 million RMB for 2025, recovering from a loss of 77.96 million RMB in the previous year due to improved operations of its subsidiary [5] - Lier Chemical anticipates a net profit of 460 million to 500 million RMB for 2025, representing a year-on-year growth of 113.62% to 132.19% due to increased demand for its products [5] Group 3: Financing and Restructuring - Zhejiang Xiantong plans to issue A-shares to no more than 35 specific investors, raising up to 1.05 billion RMB for smart manufacturing projects and working capital [7] - Longjing Environmental Protection has received acceptance from the Shanghai Stock Exchange for its securities issuance application, pending further approvals [8] Group 4: Strategic Partnerships - Fushite has signed a strategic cooperation agreement with Jiangxi Copper Group to enhance collaboration in mining equipment maintenance and expand overseas market development [15] - Pro Pharmaceutical has entered into a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., focusing on long-term collaboration in innovative drug research and outsourced production [15] Group 5: Market Activity and Stock Performance - Jia Mei Packaging's stock price increased by 230.48% from December 17, 2025, to January 6, 2026, prompting a temporary suspension for investigation due to significant price volatility [11] - Guosheng Technology's stock experienced a 370.20% increase from October 31, 2025, to January 6, 2026, leading to a suspension for review due to potential irrational market behavior [20]

Group 1 - The core viewpoint of the article is the announcement of the termination of control right change plans by Baohua Pharmaceutical and Siwei Liekong, indicating stability in their operations and financial conditions [3][6][10]. Group 2 - Baohua Pharmaceutical's stock was suspended on December 29, 2025, due to potential control right changes, with a recent market capitalization of 4.707 billion [4][13]. - Prior to suspension, Baohua Pharmaceutical's stock price increased by 6.54% and 5.88% in the two trading days leading up to the announcement [4][13]. - For the first three quarters of 2025, Baohua Pharmaceutical reported revenue of 299 million, a year-on-year increase of 2.74%, and a net profit of 32.67 million, up 36.41% year-on-year [6]. Group 3 - Siwei Liekong's stock was also suspended on December 29, 2025, with a total market capitalization of 10.6 billion [7][9]. - The company stated that the termination of the control right change plan would not have a significant adverse impact on its operational performance and financial status [10].

Company Announcements - Jia Mei Packaging's stock price increased by 230% from December 17, 2025, to January 6, 2026, leading to a suspension for investigation starting January 7, 2026 [2] - Guosheng Technology's stock rose by 370.2% during the same period, prompting a suspension for investigation effective January 7, 2026 [3] - Fenglong Co., Ltd. indicated that it may apply for a suspension if its stock price continues to rise abnormally [4] - Xinfang Pharmaceutical is facing public prosecution for alleged unit bribery [7] - Shengke Communication's second-largest shareholder plans to reduce its stake by no more than 3% [8] - Chip Origin Technology completed the acquisition of Zhudian Semiconductor [9] - Robotech's subsidiary signed a significant contract for automatic optical switch packaging with a Swiss client [10] - Aerospace Changfeng clarified that it does not engage in brain-computer interface or commercial aerospace businesses [12] - Chengjian Development holds 18.91 million shares of Century Space, making it the fourth-largest shareholder [13] - Sanbo Brain Science is not involved in the research, production, or sales of brain-computer interface products [14] - Weisi Medical's new products in the brain-computer interface field are still in the early market cultivation stage [16] - Mairande's products in the brain-computer interface area are also in the research and market cultivation phase [17] - Guankang Technology plans to acquire 100% of Liaojing Electronics, with stock resuming trading [19] - Yahui Long signed a strategic cooperation framework agreement with Brain Machine Star Chain to expand its presence in the brain-computer interface field [20] - China Satellite Communications warned that its stock price is at a historical high and may experience a significant drop [21] - Beidou Star Communication stated that commercial aerospace is just one application scenario for its products and services [22] Financial Performance - Lier Chemical expects a net profit increase of 113.62% to 132.19% for 2025 [39] - Zhongtai Co., Ltd. anticipates a net profit of 420 million to 480 million yuan for 2025, recovering from a previous loss [38] Financing and Capital Increase - Desai Xiwai is planning to issue H-shares and list on the Hong Kong Stock Exchange [40] - Xingye Yinx is also preparing to issue H-shares for listing on the Hong Kong Stock Exchange [41] Other Significant Events - Baotailong's controlling shareholder was ordered to rectify its failure to fulfill a shareholding increase commitment [42] - *ST Changyao's stock may face termination of listing due to negative net assets and other financial issues [43]